CN Patent

CN109963855A — 一种btk激酶抑制剂的结晶形式及制备方法

Assigned to Jiangsu Hengrui Medicine Co Ltd · Expires 2019-07-02 · 7y expired

What this patent protects

本发明涉及一种BTK激酶抑制剂的结晶形式及制备方法。具体地，本发明涉及(R)‑1‑(1‑丙烯酰哌啶‑3‑基)‑4‑氨基‑3‑(4‑(2,6‑二氟苯氧基)苯基)‑1,6‑二氢‑7H‑吡咯并[2,3‑d]哒嗪‑7‑酮(式(I)化合物)的II型结晶及制备方法。本发明所得到式(I)化合物的II型结晶具备良好的化学稳定性和晶型稳定性，并且所用结晶溶剂低毒低残留，可更好地用于临床治疗。

USPTO Abstract

本发明涉及一种BTK激酶抑制剂的结晶形式及制备方法。具体地，本发明涉及(R)‑1‑(1‑丙烯酰哌啶‑3‑基)‑4‑氨基‑3‑(4‑(2,6‑二氟苯氧基)苯基)‑1,6‑二氢‑7H‑吡咯并[2,3‑d]哒嗪‑7‑酮(式(I)化合物)的II型结晶及制备方法。本发明所得到式(I)化合物的II型结晶具备良好的化学稳定性和晶型稳定性，并且所用结晶溶剂低毒低残留，可更好地用于临床治疗。

Drugs covered by this patent

Patent Metadata

Patent number: CN109963855A
Jurisdiction: CN
Classification: —
Expires: 2019-07-02
Drug substance claim: No
Drug product claim: No
Assignee: Jiangsu Hengrui Medicine Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.